Compare OPY & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPY | CMPS |
|---|---|---|
| Founded | 1881 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.4M | 598.7M |
| IPO Year | N/A | 2020 |
| Metric | OPY | CMPS |
|---|---|---|
| Price | $71.98 | $6.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.43 |
| AVG Volume (30 Days) | 35.1K | ★ 1.5M |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 16.17 | N/A |
| EPS | ★ 7.46 | N/A |
| Revenue | ★ $1,453,063,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.47 | ★ N/A |
| Revenue Growth | ★ 13.48 | N/A |
| 52 Week Low | $49.26 | $2.25 |
| 52 Week High | $79.99 | $7.09 |
| Indicator | OPY | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 67.40 |
| Support Level | $66.73 | $4.90 |
| Resistance Level | $69.58 | $5.57 |
| Average True Range (ATR) | 1.99 | 0.37 |
| MACD | 0.59 | 0.18 |
| Stochastic Oscillator | 89.82 | 88.30 |
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.